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Abstract
Background:  B o n y  m e t a s t a s e s  w e r e  o ccasionally the initial presentations of malignancy.
Overlooking of bony changes on radiographs in cancer patients with non-specific clinical symptoms
may lead to delayed diagnosis.
Case presentation: We presented a 70-year-old male having hypercalcemia and diffuse
osteoblastic bone metastases on routine plain films. Finally, prostate cancer was diagnosed with a
prostate needle biopsy.
Conclusion: Although the modern radionuclide bone scanning is useful in diagnosis, osteoblastic
bone changes are occasionally seen in plain films, which are frequently overlooked. To avoid
delayed diagnosis, bony structures should be carefully examined in all plain-film radiographs.
Background
Bone metastases of malignant neoplasm are common,
especially in breast, lung and prostate cancer. Bone metas-
tases of prostate cancer are usually osteoblastic which
might be related to osteoblasts [1]. The recognition of
bony changes in patients with prostate cancer may help in
initially diagnosis, making treatment strategy and progno-
sis evaluation [2].
Case presentation
A 70-year-old man presented with poor appetite and gen-
eral malaise of two month's duration. Physical examina-
tion revealed mildly distended abdomen and hypoactive
bowel sounds. Hemogram showed high white blood cell
count (22070/μl) with 91.5% segment form and low
hemoglobin level (7.0 g/dl). Biochemical examination
showed elevated serum calcium level (2.7 mmole/l). Uri-
nary analysis showed hematuria (numerous red blood
cells per high power field in sediment examination). The
serum prostate-specific antigen (PSA) was 100 ng/ml. A
chest radiograph (figure 1) showed diffuse osteoblastic
bone lesions. In addition to dilated bowel loops with
feces, an abdominal radiograph (figure 2) showed multi-
ple patchy osteoblastic changes of bones. A malignant dis-
ease with multiple osteoblastic bone metastases was
highly suspected. Finally, prostate cancer was diagnosed
with a prostate needle biopsy. He received bilateral
orchiectomy and hormone therapy for stage IV disease.
Unfortunately, he passed away 1 month later because of
urosepsis.
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Discussion
Prostate cancer frequently metastasised to vertebrae and
pelvis, where it produced predominantly osteoblastic
lesions and local bone formation, and adversely affected
quality of life and mortality [2]. In these patients, curative
therapy was impossible and palliative treatment became
the only option. Besides, bone metastatic prostate cancer
could lead to disturbances of calcium metabolism and the
presence of hypercalcemia was significantly associated
with poor prognosis [3]. To date no definite benefit of
bone targeted therapy was evidenced, and further investi-
gation was needed [4].
Currently, conventional technetium-99m methylene dio-
phosphate (Tc-99m MDP) bone scan and positron emis-
sion tomography with 18F-2-deoxyglucose (FDG-PET)
were popular in the detection of malignant bone metas-
tases [5]. In addition, whole body magnetic resonance
imaging using diffusion-weighted images was shown to
be an alternative to detect bone metastasis [6]. However,
osteolytic or osteoblastic bone metastases were occasion-
ally seen in routine plain-film radiographs. Identification
of bony changes in plain film may contribute to the initial
diagnosis of metastatic cancer
Conclusion
Although the modern radionuclide bone scanning is use-
ful in diagnosis, osteoblastic bone changes are occasion-
ally seen in plain films, which are frequently overlooked.
To avoid delayed diagnosis, bony structures should be
carefully examined in all plain-film radiographs.
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Chest radiograph showing osteoblastic changes of spine,  scapulae, clavicles and ribs (arrow: right 4th rib with more  conspicuous change) Figure 1
Chest radiograph showing osteoblastic changes of 
spine, scapulae, clavicles and ribs (arrow: right 4th rib 
with more conspicuous change).
Abdominal radiograph showing osteoblastic changes of spine,  pelvic and femoral bones (arrows) Figure 2
Abdominal radiograph showing osteoblastic changes 
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